Portola Pharmaceuticals, Inc.
270 E. Grand Avenue
South San Francisco
California
94080
United States
Tel: 650.246.7000
Fax: 650.246.7376
Website: http://www.portola.com/
Email: contact@portola.com
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic conditions. The Company's first two commercialized products are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed in Europe as Ondexxya® (andexanet alfa), and Bevyxxa® (betrixaban). The company also is advancing cerdulatinib, a SYK/JAK inhibitor being developed for the treatment of hematologic cancers. Founded in 2003 in South San Francisco, California, Portola has operations in the United States and Europe.
Stock Exchange: NASDAQ
Stock Symbol: PTLA
269 articles about Portola Pharmaceuticals, Inc.
-
Portola Pharmaceuticals, Inc. Announces Release of Lock-up Restriction for Common Stock Held by a Director of the Company
10/16/2013
-
Portola Pharmaceuticals, Inc. Announces Proposed Offering of Common Stock
10/16/2013
-
Portola Pharmaceuticals, Inc. Announces First Phase 2 Results Demonstrating Extended Duration Infusion With Andexanet Alfa (PRT4445*) Provides Prolonged Reversal of Anticoagulation Activity of Factor Xa Inhibitor Eliquis®
10/15/2013
-
Portola Pharmaceuticals, Inc. Announces Initiation of Phase 1/2 Clinical Study of PRT2070
10/9/2013
-
Portola Pharmaceuticals, Inc. Announces Participation at Upcoming Investor Conferences
9/5/2013
-
Portola Pharmaceuticals, Inc. Reports Second Quarter Financial Results and Provides Corporate Update
8/15/2013
-
Portola Pharmaceuticals, Inc. to Announce Second Quarter 2013 Financial Results and Host Conference Call on Thursday, August 15, 2013
8/8/2013
-
Portola Pharmaceuticals, Inc. to Ring the NASDAQ Stock Market Opening Bell
8/2/2013
-
Portola Pharmaceuticals, Inc. Announces Positive Phase 2 Study Results Showing Factor Xa Inhibitor Antidote PRT4445 Reverses Anticoagulant Activity of Eliquis®
7/2/2013
-
Portola Pharmaceuticals, Inc. to Initiate Phase 2 Study Evaluating the Safety and Effectiveness of Its Factor Xa Inhibitor Antidote PRT4445 in Reversing the Anticoagulant Activity of Investigational Factor Xa Inhibitor Edoxaban
6/28/2013
-
Portola Pharmaceuticals, Inc. Announces Oral Presentation of Phase 2 Data on PRT4445, Factor Xa Inhibitor Antidote, at 2013 International Society on Thrombosis and Haemostasis Congress
6/26/2013
-
Portola Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Over-Allotment Option Exercise
5/30/2013
-
Portola Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
5/23/2013
-
Portola Pharmaceuticals, Inc. Announces Oral Presentation of Data on PRT4445, Factor Xa Inhibitor Antidote, at ATVB Scientific Sessions
4/30/2013
-
Portola Pharmaceuticals, Inc. Files for $115 Million IPO
4/15/2013
-
Aciex Therapeutics Enters Into Collaborative Research Agreement With Portola Pharmaceuticals, Inc. to Develop Dual Syk/JAK Inhibitors for Ophthalmic Indications
2/27/2013
-
Bayer AG, Johnson & Johnson Sign Partner Deal With Portola Pharmaceuticals, Inc. for Xarelto Antidote
2/5/2013
-
Portola Pharmaceuticals, Inc. Initiates Phase 2 Study of PRT4445, Universal Antidote for Factor Xa Inhibitor Anticoagulants
12/10/2012
-
Portola Pharmaceuticals, Inc. Announces Data Presentations From Thrombosis and Syk/JAK Franchises at American Society of Hematology Annual Meeting
12/6/2012
-
Pfizer Inc., Bristol-Myers Squibb Company to Fund Study of Portola Pharmaceuticals, Inc.'s Blood-Thinner Antidote
11/2/2012